Zydus Lifesciences Limited, an innovation-driven global life sciences company, announced that its subsidiary, Zydus Worldwide DMCC, has signed a definitive agreement to acquire Assertio Holdings, Inc., a U.S.-based pharmaceutical company specializing in specialty and oncology supportive-care therapies.
The acquisition will be executed through Zara Merger Sub Inc., a wholly owned acquisition subsidiary of Zydus Worldwide. Under the agreement, Zydus will acquire all outstanding shares of Assertio at USD 23.50 per share in cash, valuing the transaction at approximately USD 166.4 million on a fully diluted basis. The move marks another significant step in Zydus’ strategy to strengthen its global specialty pharmaceutical business while expanding its commercial presence in the United States.
Acquisition Provides Established Oncology Commercial Platform
With this transaction, Zydus gains access to Assertio’s established specialty oncology commercial platform in the U.S., particularly its strong position in the oncology supportive-care segment. A key asset in Assertio’s portfolio is ROLVEDON® (eflapegrastim-xnst), a long-acting granulocyte colony-stimulating factor (G-CSF) biologic approved by the U.S. Food and Drug Administration (USFDA). The therapy is indicated for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy.
ROLVEDON® is administered once per chemotherapy cycle and has secured a growing presence within the oncology supportive-care market. By integrating this asset into its portfolio, Zydus aims to enhance its specialty oncology offerings while strengthening relationships with oncology healthcare providers across the United States.
Leveraging Commercial Capabilities for Future Growth
Beyond the product portfolio, the acquisition provides Zydus with Assertio’s focused commercial infrastructure, experienced sales organization, and established oncology network. As a result, Zydus plans to leverage these capabilities to accelerate the development and commercialization of future specialty and oncology therapies. The company views the transaction as an opportunity to build a broader, differentiated oncology business in one of the world’s largest pharmaceutical markets.
Leadership Perspective
Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, emphasized the strategic importance of the transaction for the company’s long-term growth ambitions. “This transaction represents a strategic step in strengthening our specialty and oncology footprint in the U.S. Assertio brings a focused commercial platform and an approved oncology asset that aligns well with our long-term strategy of building differentiated, durable specialty businesses globally,” he said.
Advancing Zydus’ Global Specialty and Oncology Strategy
The acquisition underscores Zydus Lifesciences’ commitment to expanding its specialty pharmaceutical portfolio and enhancing its presence in high-growth therapeutic segments. By combining Assertio’s commercial capabilities with Zydus’ global development and manufacturing strengths, the company is positioning itself to become a stronger player in the U.S. oncology and specialty pharmaceutical market. As per company press release, as demand for innovative cancer therapies and supportive-care solutions continues to rise, the transaction is expected to support Zydus’ long-term vision of building a sustainable, globally competitive specialty healthcare business.
